A poster summarizing the results of the Phase 1b portion of the study SAKK 66/17 concerning the combination of thermal ablation with Immunophotonics’s lead asset, IP-001TM, in patients with advanced solid tumors was presented at the ESMO Immuno-Oncology Congress on December 7-9, 2022, in Geneva, Switzerland. The ESMO Congress is one of Europe’s premier events for showcasing the latest advances in the treatment of cancer. Immunophotonics is partnering with the Swiss Group for Clinical Cancer Research (SAKK) for the SAKK 66/17 clinical trial, which has advanced into its Phase 2a portion. Click here to view the poster details.
